The influence of pieces thickness on metallographic structure of welded joints

The main objective of this paper was to establish how the thickness of welded pieces influences the metallographic structure of welded joints. Thus were made a total of 6 samples, and from each sample were taken test specimens for metallographic analysis of the base material, the filler material respective heat affected zone (HAZ). The samples were carried out by welding process: metal active gases (MAG) using a steel E 36-4, and the welded pieces had a thickness between 10 and 24 mm. The welding regime was characterized by parameters Iw = 200 / A, Uw = 24 / V. The joint by welding pieces was “T” form and both piece used as the base and the piece used as heart for welded joint were made of sheets with different thicknesses

Sintering the beaks of the elevator manufactured by direct metal laser sintering (DMLS) process from Co - Cr alloy

In this paper, two prototypes of dental elevator was made by DMLS process, using a super alloy powder of Co – Cr (ST2724G), with Phenix Systems machine, type PXS & PXM Dental, one with a threaded tail and another with a cylindrical tail. The quality obtained for the elevator is better, thanks to the material used and to the manufacturing process. For the elevator prototypes there were performed some Finite element method (FEM) analysis to identify stress locations and displacements. It was realized corrosion test in artificial saliva Fusayama Meyer (pH 5,5) at temperature of 37 ± 1 °C for 24 hours and remarks the importance of post treatment after DMLS process to obtain a better corrosion resistance in vitro

Augmented reality simulation of CAM spatial tool paths in prismatic milling sequences

© IFIP International Federation for Information Processing 2016. Augmented Reality (AR) technology to support learning activities becomes a trend in education and effective teaching aids for engineering courses. This paper presents initial results of a project aimed to transform the current learning process of Computer Aided Manufacturing (CAM) by designing and implementing an interactive AR learning and simulation tool to help students to develop a comprehensive understanding of technological models and features in milling processes. We present a marker-based platform that uses AR as a medium for representation of prismatic milling processes to facilitate CAM education and it should enable a faster comprehension of complex spatial paths and overall machining system

Sintering the beaks of the elevator manufactured by direct metal laser sintering (DMLS) process from Co - Cr alloy

In this paper, two prototypes of dental elevator was made by DMLS process, using a super alloy powder of Co – Cr (ST2724G), with Phenix Systems machine, type PXS & PXM Dental, one with a threaded tail and another with a cylindrical tail. The quality obtained for the elevator is better, thanks to the material used and to the manufacturing process. For the elevator prototypes there were performed some Finite element method (FEM) analysis to identify stress locations and displacements. It was realized corrosion test in artificial saliva Fusayama Meyer (pH 5,5) at temperature of 37 ± 1 °C for 24 hours and remarks the importance of post treatment after DMLS process to obtain a better corrosion resistance in vitro

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events